BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Umutesi J, Simmons B, Makuza JD, Dushimiyimana D, Mbituyumuremyi A, Uwimana JM, Ford N, Mills EJ, Nsanzimana S. Prevalence of hepatitis B and C infection in persons living with HIV enrolled in care in Rwanda. BMC Infect Dis 2017;17:315. [PMID: 28464899 DOI: 10.1186/s12879-017-2422-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Gupta N, Mbituyumuremyi A, Kabahizi J, Ntaganda F, Muvunyi CM, Shumbusho F, Musabeyezu E, Mukabatsinda C, Ntirenganya C, Van Nuil JI, Kateera F, Camus G, Damascene MJ, Nsanzimana S, Mukherjee J, Grant PM. Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir-sofosbuvir (SHARED): a single-arm trial. Lancet Gastroenterol Hepatol 2019;4:119-26. [PMID: 30552056 DOI: 10.1016/S2468-1253(18)30382-0] [Cited by in Crossref: 38] [Cited by in F6Publishing: 15] [Article Influence: 9.5] [Reference Citation Analysis]
2 Singh KP, Crane M, Audsley J, Avihingsanon A, Sasadeusz J, Lewin SR. HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment. AIDS 2017;31:2035-52. [PMID: 28692539 DOI: 10.1097/QAD.0000000000001574] [Cited by in Crossref: 120] [Cited by in F6Publishing: 71] [Article Influence: 24.0] [Reference Citation Analysis]
3 Oluremi AS, Opaleye OO, Ogbolu DO, Alli OAT, Ashiru FT, Alaka OO, Suleiman IE, Enitan SS, Adelakun AA, Adediji IO, Olowoyeye EA, Adewumi OO, Ayodele TO, Ogunleke OA. Serological evidence of HIV, Hepatitis B, C, and E viruses among liver disease patients attending tertiary hospitals in Osun State, Nigeria. J Immunoassay Immunochem 2021;42:69-81. [PMID: 32967530 DOI: 10.1080/15321819.2020.1821214] [Reference Citation Analysis]
4 Johnson TM, Klepser DG, Bares SH, Scarsi KK. Predictors of vaccination rates in people living with HIV followed at a specialty care clinic. Hum Vaccin Immunother 2021;17:791-6. [PMID: 32881642 DOI: 10.1080/21645515.2020.1802163] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Makuza JD, Rwema JOT, Ntihabose CK, Dushimiyimana D, Umutesi J, Nisingizwe MP, Serumondo J, Semakula M, Riedel DJ, Nsanzimana S. Prevalence of hepatitis B surface antigen (HBsAg) positivity and its associated factors in Rwanda. BMC Infect Dis 2019;19:381. [PMID: 31053097 DOI: 10.1186/s12879-019-4013-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
6 Semá Baltazar C, Boothe M, Kellogg T, Ricardo P, Sathane I, Fazito E, Raymond HF, Temmerman M, Luchters S. Prevalence and risk factors associated with HIV/hepatitis B and HIV/hepatitis C co-infections among people who inject drugs in Mozambique. BMC Public Health 2020;20:851. [PMID: 32493347 DOI: 10.1186/s12889-020-09012-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
7 Souda S, Mwita JC, Cainelli F, Mannathoko NB, Anderson M, Moyo S. Seroprevalence and risk factors of hepatitis B, C and D virus infection amongst patients with features of hepatitis in a referral hospital in Botswana: A cross-sectional study. Southern African Journal of Infectious Diseases 2021;36. [DOI: 10.4102/sajid.v36i1.275] [Reference Citation Analysis]
8 Umutesi J, Liu CY, Penkunas MJ, Makuza JD, Ntihabose CK, Umuraza S, Niyikora J, Serumondo J, Gupta N, Nsanzimana S. Screening a nation for hepatitis C virus elimination: a cross-sectional study on prevalence of hepatitis C and associated risk factors in the Rwandan general population. BMJ Open 2019;9:e029743. [PMID: 31272986 DOI: 10.1136/bmjopen-2019-029743] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
9 Kafeero HM, Ndagire D, Ocama P, Walusansa A, Sendagire H. Sero-prevalence of human immunodeficiency virus-hepatitis B virus (HIV-HBV) co-infection among pregnant women attending antenatal care (ANC) in sub-Saharan Africa (SSA) and the associated risk factors: a systematic review and meta-analysis.Virol J. 2020;17:170. [PMID: 33160386 DOI: 10.1186/s12985-020-01443-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
10 Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. Clin Microbiol Rev. 2020;33. [PMID: 32102898 DOI: 10.1128/cmr.00046-19] [Cited by in Crossref: 37] [Cited by in F6Publishing: 20] [Article Influence: 18.5] [Reference Citation Analysis]
11 Makuza JD, Nisingizwe MP, Rwema JOT, Dushimiyimana D, Habimana DS, Umuraza S, Serumondo J, Ngwije A, Semakula M, Gupta N, Nsanzimana S, Janjua NZ. Role of unsafe medical practices and sexual behaviours in the hepatitis B and C syndemic and HIV co-infection in Rwanda: a cross-sectional study. BMJ Open 2020;10:e036711. [PMID: 32660951 DOI: 10.1136/bmjopen-2019-036711] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Clement ME, Collins LF, Wilder JM, Mugavero M, Barker T, Naggie S. Hepatitis C Virus Elimination in the Human Immunodeficiency Virus-Coinfected Population: Leveraging the Existing Human Immunodeficiency Virus Infrastructure. Infect Dis Clin North Am 2018;32:407-23. [PMID: 29778263 DOI: 10.1016/j.idc.2018.02.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
13 Mbituyumuremyi A, Van Nuil JI, Umuhire J, Mugabo J, Mwumvaneza M, Makuza JD, Umutesi J, Nsanzimana S, Gupta N. Controlling hepatitis C in Rwanda: a framework for a national response. Bull World Health Organ 2018;96:51-8. [PMID: 29403100 DOI: 10.2471/BLT.16.183772] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
14 Umutesi G, Shumbusho F, Kateera F, Serumondo J, Kabahizi J, Musabeyezu E, Ngwije A, Gupta N, Nsanzimana S. Rwanda launches a 5-year national hepatitis C elimination plan: A landmark in sub-Saharan Africa. J Hepatol. 2019;70:1043-1045. [PMID: 30948269 DOI: 10.1016/j.jhep.2019.03.011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
15 Mathur P, Comstock E, Makuza JD, Emmanuel B, Sebeza J, Kiromera A, Wilson E, Kattakuzhy S, Nelson A, Kottilil S, Riedel DJ. Implementation of a unique hepatitis C care continuum model in Rwanda. J Public Health (Oxf) 2019;41:e203-8. [PMID: 29982813 DOI: 10.1093/pubmed/fdy115] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Van Nuil JI, Umutesi G, Shumbusho F, Kateera F, Dushimimana JD, Muvunyi CM, Musabeyezu E, Mukabatsinda C, Ntirenganya C, Kabahizi J, Serumondo J, Makuza JD, Nsanzimana S, Grant P, Gupta N. Improved quality of life following direct-acting antiviral treatment for chronic hepatitis C infection in Rwanda: Results from a clinical trial in sub-Saharan Africa (the SHARED study). J Viral Hepat 2021;28:112-20. [PMID: 32858774 DOI: 10.1111/jvh.13386] [Reference Citation Analysis]
17 Kafeero HM, Ndagire D, Ocama P, Kudamba A, Walusansa A, Sendagire H. Prevalence and predictors of hepatitis B virus (HBV) infection in east Africa: evidence from a systematic review and meta-analysis of epidemiological studies published from 2005 to 2020. Arch Public Health 2021;79:167. [PMID: 34537079 DOI: 10.1186/s13690-021-00686-1] [Reference Citation Analysis]
18 Umutesi J, Klett-tammen C, Nsanzimana S, Krause G, Ott JJ. Cross-sectional study of chronic hepatitis B virus infection in Rwandan high-risk groups: unexpected findings on prevalence and its determinants. BMJ Open 2021;11:e054039. [DOI: 10.1136/bmjopen-2021-054039] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Iradukunda PG, Habyarimana T, Niyonzima FN, Uwitonze AY, Mpunga T. Risk factors associated with hepatitis B and C in rural population of Burera district, Rwanda. Pan Afr Med J 2020;35:43. [PMID: 32499858 DOI: 10.11604/pamj.2020.35.43.16226] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Munyemana JB, Mukanoheli E, Nsabimana T, Niringiyumukiza JD. HCV Seroprevalence among HIV Patients and Associated Comorbidities at One Primary Health Facility in Rwanda. Am J Trop Med Hyg 2021:tpmd200500. [PMID: 33720846 DOI: 10.4269/ajtmh.20-0500] [Reference Citation Analysis]
21 Makuza JD, Liu CY, Ntihabose CK, Dushimiyimana D, Umuraza S, Nisingizwe MP, Umutesi J, Serumondo J, Mugeni SD, Semakula M, Gupta N, Hellard M, Nsanzimana S. Risk factors for viral hepatitis C infection in Rwanda: results from a nationwide screening program. BMC Infect Dis 2019;19:688. [PMID: 31382901 DOI: 10.1186/s12879-019-4322-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]